NeuroSense Therapeutics Advances Toward Canadian Fast-Track Approval for ALS Drug

NeuroSense Therapeutics has taken a significant step toward securing fast-track approval in Canada for its ALS treatment, PrimeC, following a constructive pre-submission meeting with Health Canada. This development not only promises to expedite access to the drug for Canadian patients but also strengthens the company's position in ongoing negotiations for a lucrative global pharma partnership. With Phase 2b trial results showing a 36% slowdown in ALS progression and a 43% improvement in survival, PrimeC's potential market impact is substantial, estimated at $100–150 million in annual peak sales in Canada alone. The outcome of this regulatory process could serve as a pivotal moment for NeuroSense, offering a blueprint for subsequent approvals in the U.S. and Europe and marking a significant milestone in the fight against ALS.